BGI's international presence

BGI Genomics & genomiQa sign WGS services agreement

GenomiQa and BGI Genomics formed an agreement, on 25 March 2019, on clinical whole genome cancer sequencing utilising BGI’s ISO15189 accredited laboratory sequencing facilities. GenomiQa also intends to use BGI’s facility in Australia, once it has completed the ISO 15189 accreditation process, which is anticipated within the next 12 months. Keep reading 

MGI Launches its Most Powerful Genetic Sequencer

MGI launched its most powerful genetic sequencer in October 2018 MGISEQ-T7, built with innovative quadruple flowcell staging that allows simultaneous but independent operation of 1 to 4 flowcells in a single run. The MGI proprietary gene sequencing technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flowcell, fluid, and biochemical and optical system. T7 takes the production capacity of the sequencer to a new level with daily output of data up to 6Tb. Keep reading

MGI and Decode Science Form Distribution Partnership

MGI is pleased to announce the appointment of Decode Science as the distributor for the MGI range of next generation sequencers and related products in Australia and New Zealand regions. This partnership levers the strengths of both organisations to provide strong local support for customers. In true partnership the MGI Australia team and Decode Science will jointly provide after sales applications and service support to new and existing units in the market. Decode Science is a privately owned Australian organisation specialising in the Life Science market.

Genomics and AI to Predict Cancer Treatment

A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialised in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner. Keep reading

BGI Australia Celebrates 2nd Anniversary

 BGI Australia celebrated its second anniversary on 22nd August 2018. A ceremony was held in QIMR Auditorium with invited collaborators, partners, and friends. Since its humble beginning in 2016, BGI Australia has been actively developing scientific research collaborations with reputable Australian universities and research institutes in a range of arenas e.g. "imaging+genomics" cancer diagnosis, infectious disease control and prevention, marine biology and biodiversity. We thank all the guests for coming to share our happy day with us and we look forward to a successful future with you in it.  

MGI Sequencers Receive CFDA Approval

MGI has received China Food and Drug Administration (CFDA) certification for its latest two models of Next Generation genetic sequencers. MGISEQ-2000 and MGISEQ-200 sequencers have been granted the Medical Device Registration Certificate by CFDA on 25th June 2018, which makes BGI the first organisation in China to receive CFDA certification for Next Generation sequencing diagnostic products and medical devices. These sequencers will not just play an important role in scientific research, but also contribute to a wide range of applications in clinical medicine. Keep reading

BGI's presence in the world

BGI and Maxwell Plus Kick-start Collaborative Research on Prostate Cancer

BGI and Maxwell Plus have executed a collaborative research project “A model to predict risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers”. The objective is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between prevalence of prostate, breast, ovarian and colorectal cancers in patients' families. Keep reading

MOU signed on Collaborative Research and Innovation in Personalised Healthcare

BGI signs a Memorandum of Understanding (MoU) with the bio-nanotechnology innovator Xing Technologies, a UQ spin-off enterprise specialising in world-leading disease diagnosis and monitoring technologies, including cancer. The partnership will focus on collaborative research and product innovation in DNB technology, Circulating Tumour/Stem Cells technology, and point-of-care product. Keep reading

Independent Data Comparison of BGISEQ-500 to an Alternative System

Dr Andrew Carroll from DNAnexus conducted an independent side-by-side assessment of data comparison of BGISEQ 500 to Illumina NovaSeq on 2 Jul. 2018 and published the findings. The analysis is based on the three WGS data sets of NA12878/HG001 recently released, and demonstrates significant improvements relative to prior data. Keep reading 

Collaborative Efforts With QAAFI (UQ) to Establish Australia's Gene Bank

BGI signed a Memorandum of Understanding with the University of Queensland to strengthen the extensive collaboration to establish Australia's very own gene bank. “This is an important initiative that will help protect the world’s biodiversity, and lead to other innovations in food security and human health.” said Professor Robert Henry, Director of the Queensland Alliance for Agriculture and Food Innovation. Keep reading 

BGI Ranks the #1 Institution of the Most Academic Collaborations on Nature Index

On the latest Nature Index 2017 recently published, BGI ranks No.1 on the Top 50 Corporate Institutions by Number of Academic Collaborations with 642 bilateral collaborations worldwide from 2012 to 2016.  Other major multinational corporations are also named on the index e.g. Illumina, Inc. ranks the 6th with 412 collaborations; Thermo Fisher the 13th with 333 collaborations.  Keep reading

George Church Institute of Regenesis in China National Genebank

Professor George Church accepted the appointment as the Chief Scientist of the George Church Institute of Regenesis located in China National GeneBank, Shenzhen, China. BGI has made a strong commitment to support research directed by Prof. Church both in China and in the United States. The new collaboration of applied synthetic biology will initially focus on the development of enabling technologies in high-density DNA storage, biomanufacture of natural products, and genome editing for medicine and new therapy. Keep reading 

BGI's presence in the world

BGI Australia Partners with the University of Queensland (CAI)

Life Science research to benefit as global genomics specialist formalises ties with the University of Queensland Centre of Advanced Imaging (CAI) to develop early diagnostic tools for epilepsy.  “It will combine anatomical imaging data from Australia’s first ultra-high field 7T MRI with whole genome sequencing data from participants who have intractable focal epilepsy,” the Director of UQ CAI Professor David Reutens said "the research collaboration with BGI was unique and was set to boost the centre’s research, development and commercialisation." Keep reading  

BGI Australia and University of Melbourne to Expand Collaboration

BGI Australia and the University of Melbourne have signed a MOU to engage in scientific collaborations in the area of One Health using -omic and informatic technologies with the aim to build a comprehensive, world-class program and joint-centre in infectious diseases. The University’s Faculty of Veterinary and Agricultural Sciences and BGI will undertake an international-collaborative research program in areas such as genomics, transcriptomics, proteomics, bioinformatics and data mining. Keep reading 

BGI Australia Announces RFP Winners

Since the announcement of call for proposals in August 2017 BGI Australia has received 21 Expression of Interest(EOI)’s and 3 full proposals. We are sincerely appreciative of the extensive interest received from our passionate fellow Australian researchers and scientists in the biodiversity and evolution fields. We are pleased to announce the final two winners: “Managing regime shifts and fisheries collapse on the Great Barrier Reef – the role of ancient DNA” from Professor John Pandolfi and Dr. Cynthia Riginos of the University of Queensland; and “Depth adaptation and scope for vertical connectivity in scleractinian corals” from Dr. Greg Torda of James Cook University. Keep reading 

BGI Australia Laboratory Opens

Developed by global genomics company BGI, the BGISEQ-500 genome sequencer (Zebra) will operate from the company’s new Australian headquarters at the QIMR Berghofer Medical Research Institute since May 2017. It is the only genomics sequencer of its kind in the Southern Hemisphere. A ceremony was held today to mark the official launch of BGI’s new Southern Hemisphere genomics laboratory and the unveiling of the sequencer. Keep reading 

BGI Sets up Shop in Brisbane as its Asian Pacific Headquarters

Queensland's innovation agenda has received a boost with one of the world's largest gene sequencing institutes choosing to map out its Asian-Pacific expansion from Brisbane. BGI officially opened its new Australian and Asia Pacific headquarters at the QIMR Berghofer Medical Research Institute in Brisbane. BGI President and co-found Professor Jian Wang says the strength of Queensland’s existing life science institutions, industries and social network made it an obvious choice for BGI’s R&D and commercialisation centre for Asia Pacific.  Keep reading

QIMR Berghofer Signs MOU with BGI Australia

QIMR Berghofer Medical Research Institute and the Chinese genomics organisation BGI have entered into an agreement that will promote collaboration on a genomics-based research and education program.  The Memorandum of Understanding was signed at a meeting between the two world-leading research bodies in October 2016 in Shenzhen. Keep reading